ArticleEuropean radiology experimental2026
Predicting induction chemotherapy response based on tumor-stroma ratio and pretreatment synthetic MRI in nasopharyngeal carcinoma.
Article in European radiology experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
objectiveThere is no satisfactory model for predicting the therapeutic response to chemotherapy of nasopharyngeal carcinoma (NPC). We developed a nomogram using tumor-stroma ratio (TSR) and histogram features from pretreatment synthetic magnetic resonance MRI (SyMRI) to assess induction chemotherapy (IC) response in NPC. MATERIALS AND
methodsData from 185 NPC patients were retrospectively collected from July 2022 to November 2023 (training cohort), and 82 NPC patients were prospectively enrolled from December 2023 to July 2024 (test cohort). A nomogram was developed to predict IC response using logistic regression based on clinicopathological and imaging features from SyMRI T1-, T2-, and proton density (PD)-weighted images, and apparent diffusion coefficient (ADC) maps. The nomogram was validated in the test cohort.
resultsAmong the 267 patients (187 males, 80 females), with a mean age of 52.2 years (ranging 43.5-58.7), 181 were responders. Histogram features from ADC and T2-map did not differentiate non-responders (all p ≥ 0.220). A clinicopathological model based on TSR and a SyMRI model using T1map_mean and PDmap_Kurtosis were developed. In the test cohort, The nomogram, combining TSR, T1map_mean, and PDmap_Kurtosis, achieved an area under the curve (AUC) of 0.836 (95% CI: 0.690-0.914), outperforming the clinicopathological model (AUC of 0.711, 95% CI: 0.577-0.809, p = 0.015) and SyMRI model (AUC of 0.774, 95% CI: 0.623-0.822, p = 0.003).
conclusionThe nomogram combining TSR and histogram parameters from pretreatment SyMRI showed a good performance in predicting IC response for NPC, superior to those of clinicopathological and SyMRI models. RELEVANCE STATEMENT: A nomogram based on pretreatment synthetic MRI and clinicopathological features can help in selecting patients as candidates for IC. KEY POINTS: NPC patients with high TSR demonstrated sensitivity to IC. The nomogram, integrating TSR and synthetic MRI parameters, achieved a significantly high predictive performance. The nomogram may be a reliable tool for predicting the response to IC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.